We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?
Read MoreHide Full Article
Key Takeaways
Tenet Healthcare's Q3 EPS is projected to jump 24.3% to $4.60, with revenues up 3.5% to $5.47 billion.
Ambulatory Care revenues are expected to rise 8.4%, while the segment's adjusted EBITDA could grow 9.3%.
Total hospital patient days may decline 3.7%, while rising utilization costs could partly offset Q3 gains.
Hospital operator Tenet Healthcare Corporation (THC - Free Report) is set to report third-quarter 2026 results on Oct. 29, 2026, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at $4.60 per shareon revenues of $5.47 billion.
The third-quarter earnings estimate has witnessed two upward revisions and no downward movement over the past 60 days. The bottom-line projection indicates a year-over-year increase of 24.3%. Also, the Zacks Consensus Estimate for quarterly revenues suggests year-over-year growth of 3.5%.
Image Source: Zacks Investment Research
For full-year 2026, the Zacks Consensus Estimate for Tenet Healthcare’s revenues is pegged at $22.21 billion, implying a rise of 4.2% year over year. The consensus mark for 2026 earnings per share is pegged at $21.04, indicating an increase of 25.4% on a year-over-year basis.
Tenet Healthcare beat the consensus estimate for earnings in each of the trailing four quarters, with the average surprise being 22.7%, as you can see below.
Our proven model predicts a likely earnings beat for the company this time around as well. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is precisely the case here.
THC has an Earnings ESP of +11.11% and carries a Zacks Rank #3. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
What’s Shaping THC’s Q3 Results?
The Zacks Consensus Estimate for adjusted patient admissions in total hospital operations suggests a 0.7% year-over-year decline. However, on a same-hospital basis, the consensus estimate for adjusted patient admissions indicates a 1.8% increase from a year ago. The consensus mark for same hospital net patient revenues per adjusted admission in the third quarter signals a nearly 2% year-over-year increase.
Meanwhile, the Ambulatory Care business is likely to have gained from strong growth in consolidated same-facility net patient service revenues, contributions from facility acquisitions and an expansion of service lines. The consensus estimate for the Ambulatory Care segment’s net operating revenues suggests 8.4% growth from the prior-year quarter’s figure. The Zacks Consensus Estimate for adjusted EBITDAfrom Ambulatory Care operations suggests 9.3% year-over-year growth.
The Zacks Consensus Estimate for Hospital Operations and Services revenues for the third quarter is pegged at $4.09 billion, indicating a 1.9% increase from the year-ago period. Also, the Zacks Consensus Estimate for adjusted EBITDAfrom the segment suggests a 3.7% year-over-year growth.
Both the consensus estimate and our model estimate suggest that third-quarter total hospital patient days have decreased 3.7% year over year. Both the Zacks Consensus Estimate and our model estimate for the average length of stay in total hospital indicate a 3% decrease from a year ago. Also, with increased utilization, costs are expected to have increased in the third quarter, partially offsetting the positives.
Stocks That Warrant a Look
Here are some other companies worth considering from the broader Medical space, as our model shows that these, too, have the right combination of elements to beat on earnings this time around:
The Zacks Consensus Estimate for Prelude Therapeutics’ bottom line for the to-be-reported quarter signals a 46.2% improvement from a year ago, which remained stable over the past week. Its earnings beat estimates in each of the past four quarters, with an average surprise of 33.7%.
Immix Biopharma, Inc. (IMMX - Free Report) has an Earnings ESP of +5.56% and a Zacks Rank #3.
The Zacks Consensus Estimate for Immix Biopharma’s bottom line for the to-be-reported quarter indicates a 25% year-over-year improvement. It has witnessed one upward revision against no downward movement over the past 60 days.
Korsana Biosciences, Inc. (KRSA - Free Report) has an Earnings ESP of +26.45% and a Zacks Rank of 3.
The Zacks Consensus Estimate for Korsana Biosciences’ bottom line for the to-be-reported quarter indicates a 62.9% improvement from a year ago. The estimate remained stable over the past week.
View the Zacks #1 Rank List
Image: Bigstock
Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?
Key Takeaways
Hospital operator Tenet Healthcare Corporation (THC - Free Report) is set to report third-quarter 2026 results on Oct. 29, 2026, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at $4.60 per shareon revenues of $5.47 billion.
The third-quarter earnings estimate has witnessed two upward revisions and no downward movement over the past 60 days. The bottom-line projection indicates a year-over-year increase of 24.3%. Also, the Zacks Consensus Estimate for quarterly revenues suggests year-over-year growth of 3.5%.
For full-year 2026, the Zacks Consensus Estimate for Tenet Healthcare’s revenues is pegged at $22.21 billion, implying a rise of 4.2% year over year. The consensus mark for 2026 earnings per share is pegged at $21.04, indicating an increase of 25.4% on a year-over-year basis.
Tenet Healthcare beat the consensus estimate for earnings in each of the trailing four quarters, with the average surprise being 22.7%, as you can see below.
Tenet Healthcare Price and EPS Surprise
Tenet Healthcare Corporation price-eps-surprise | Tenet Healthcare Corporation Quote
Q3 Earnings Whispers for THC
Our proven model predicts a likely earnings beat for the company this time around as well. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is precisely the case here.
THC has an Earnings ESP of +11.11% and carries a Zacks Rank #3. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
What’s Shaping THC’s Q3 Results?
The Zacks Consensus Estimate for adjusted patient admissions in total hospital operations suggests a 0.7% year-over-year decline. However, on a same-hospital basis, the consensus estimate for adjusted patient admissions indicates a 1.8% increase from a year ago. The consensus mark for same hospital net patient revenues per adjusted admission in the third quarter signals a nearly 2% year-over-year increase.
Meanwhile, the Ambulatory Care business is likely to have gained from strong growth in consolidated same-facility net patient service revenues, contributions from facility acquisitions and an expansion of service lines. The consensus estimate for the Ambulatory Care segment’s net operating revenues suggests 8.4% growth from the prior-year quarter’s figure. The Zacks Consensus Estimate for adjusted EBITDAfrom Ambulatory Care operations suggests 9.3% year-over-year growth.
The Zacks Consensus Estimate for Hospital Operations and Services revenues for the third quarter is pegged at $4.09 billion, indicating a 1.9% increase from the year-ago period. Also, the Zacks Consensus Estimate for adjusted EBITDAfrom the segment suggests a 3.7% year-over-year growth.
Both the consensus estimate and our model estimate suggest that third-quarter total hospital patient days have decreased 3.7% year over year. Both the Zacks Consensus Estimate and our model estimate for the average length of stay in total hospital indicate a 3% decrease from a year ago. Also, with increased utilization, costs are expected to have increased in the third quarter, partially offsetting the positives.
Stocks That Warrant a Look
Here are some other companies worth considering from the broader Medical space, as our model shows that these, too, have the right combination of elements to beat on earnings this time around:
Prelude Therapeutics Incorporated (PRLD - Free Report) has an Earnings ESP of +9.72% and a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Prelude Therapeutics’ bottom line for the to-be-reported quarter signals a 46.2% improvement from a year ago, which remained stable over the past week. Its earnings beat estimates in each of the past four quarters, with an average surprise of 33.7%.
Immix Biopharma, Inc. (IMMX - Free Report) has an Earnings ESP of +5.56% and a Zacks Rank #3.
The Zacks Consensus Estimate for Immix Biopharma’s bottom line for the to-be-reported quarter indicates a 25% year-over-year improvement. It has witnessed one upward revision against no downward movement over the past 60 days.
Korsana Biosciences, Inc. (KRSA - Free Report) has an Earnings ESP of +26.45% and a Zacks Rank of 3.
The Zacks Consensus Estimate for Korsana Biosciences’ bottom line for the to-be-reported quarter indicates a 62.9% improvement from a year ago. The estimate remained stable over the past week.